1.Hudson, JI, Hiripi, E, Pope, HG, Kessler, RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348–358.
2.Kessler, RC, Berglund, PA, Chiu, WT, et al.The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73(9):904–914.
3.Udo, T, Grilo, CM. Prevalence and correlates of DSM-5-defined eating disorders in a nationally representative sample of US adults. Biol Psychiatry. 2018;84(5):345–354.
4.Galmiche, M, Déchelotte, P, Lambert, G, Tavolacci, MP. Prevalence of eating disorders over the 2000-2018 period: a systematic literature review. Am J Clin Nutr. 2019;109(5):1402–1413.
5.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Philadelphia, PA: American Psychiatric Publishing; 2013.
6.Udo, T, Grilo, CM. Psychiatric and medical correlates of DSM-5 eating disorders in a nationally representative sample of adults in the United States. Int J Eat Disord. 2019;52(1):42–50.
7.Swanson, SA, Crow, SJ, Le Grange, D, Swendsen, J, Merikangas, KR. Prevalence and correlates of eating disorders in adolescents. Results from the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry. 2011;68(7):714–723.
8.Ágh, T, Kovács, G, Pawaskar, M, et al.Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review. Eat Weight Disord. 2015;20(1):1–12.
9.Mitchell, JE. Medical comorbidity and medical complications associated with binge-eating disorder. Int J Eat Disord. 2016;49(3):319–323.
10.Olguin, P, Fuentes, M, Gabler, G, Guerdjikova, AI, Keck, PE, McElroy, SL. Medical comorbidity of binge eating disorder. Eat Weight Disord. 2017;22:13–26.
11.Sonneville, KR, Horton, NJ, Micali, N, et al.Longitudinal associations between binge eating and overeating and adverse outcomes among adolescents and young adults: does loss of control matter? JAMA Pediatr. 2013;167(2):149–155.
12.Field, AE, Sonneville, KR, Micali, N, et al.Prospective association of common eating disorders and adverse outcomes. Pediatrics. 2012;130(2):e289–e295.
13.Coffino, JA, Udo, T, Grilo, CM. Rates of help-seeking in US adults with lifetime DSM-5 eating disorders: prevalence across diagnoses and differences by sex and ethnicity/race. Mayo Clin Proc. 2019;94:1415–1426. doi:10.1016/j.mayocp.2019.02.030.
14.Reas, DL, Grilo, CM. Pharmacological treatment of binge eating disorder: update review and synthesis. Expert Opin Pharmacother. 2015;16(10):1463–1478.
15.McElroy, SL, Hudson, JI, Mitchell, JE, Wilfley, D, Ferreira-Cornwell, C. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235–246.
16.Brownley, KA, Berkman, ND, Peat, CM, et al.Binge-eating disorder in adults: a systematic review and meta-analysis. Ann Intern Med. 2016;165:409–420.
17.McElroy, SL, Hudson, J, Ferreira-Cornwell, MC, Radewonuk, J, Whitaker, T, Gasior, M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41(5):1251–1260.
18.McElroy, SL. Pharmacologic treatments for binge-eating disorder. J Clin Psychiatry. 2017;78(suppl 1):14–19.
19.Hudson, JI, McElroy, SL, Ferreira-Cornwell, MC, Radewonuk, J, Gasior, M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):903–910.
20.Grilo, CM. Psychological and behavioral treatments for binge-eating disorder. J Clin Psychiatry. 2017;78(suppl 1):20–24.
21.Hilbert, A, Petroff, D, Herpertz, S, et al.Meta-analysis of the efficacy of psychological and medical treatments for binge-eating disorder. J Consult Clin Psychol. 2019;87(1):91–105. doi:10.1037/ccp0000358.
22.Hopkins, SC, Sunkaraneni, S, Skende, E, et al.Pharmacokinetics and exposure-response relationships of dasotraline in the treatment of ADHD in adults. Clin Drug Investig. 2016;36(2):137–146.
23.Koblan, KS, Hopkins, SC, Sarma, K, et al.Dasotraline for the treatment of ADHD: a randomized, double-blind, placebo-controlled, proof of concept trial in adults. Neuropsychopharmacology. 2015;40(12):2745–2752.
24.Heal, DJ, Vickers, SP, Hopkins, SC, Koblan, KS. Investigation of the effects of dasotraline in a validated rat model of binge-eating disorder. Neuropsychopharmacol. 2018; S34–S35.
25.McElroy, SL, Hudson, JI, Grilo, CM, et al.Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial. J Clin Psychiatry. in press.
26.First, MB, Williams, JBW, Spitzer, RL, Gibbon, M. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2007.
27.Fairburn, CG, Beglin, SJ. Assessment of eating disorders: interview or self-report questionnaire? Int J Eat Disord. 1994;16(4):363–370.
28.Grilo, CM, Masheb, RM, Wilson, GT. A comparison of different methods for assessing the features of eating disorders in patients with binge eating disorder. J Consult Clin Psychol. 2001;69(2):317–322.
29.Reas, DL, Grilo, CM, Masheb, RM. Reliability of the Eating Disorder Examination-Questionnaire in patients with binge eating disorder. Behav Res Ther. 2006;44(1):43–51.
30.Ruikar, V. Interactive voice/web response system in clinical research. Perspect Clin Res. 2016;7(1):15–20.
31.Deal, LS, Wirth, RJ, Gasior, M, Herman, BK, McElroy, SL. Validation of the Yale-Brown obsessive-compulsive scale modified for binge eating. Int J Eat Disord. 2015;48(7):994–1004.
32.Grilo, CM, Reas, DL, Hopwood, CJ, Crosby, RD. Factor structure and construct validity of the Eating Disorder Examination-Questionnaire in college students: further support for a modified brief version. Int J Eat Disord. 2015;48(3):284–289.
33.Machado, PPP, Grilo, CM, Crosby, RD. Replication of a modified factor structure for the Eating Disorder Examination-Questionnaire: extension to clinical eating disorder and non-clinical samples in Portugal. Eur Eat Disord Rev. 2018;26(1):75–80.
34.Sheehan, D. The Anxiety Disease. New York, NY: Bantam Books; 1983.
35.Posner, K, Brown, GK, Stanley, B, et al.The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277.
35.Kampman, KM, Volpicelli, JR, McGinnis, DE, et al.Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav. 1998;23(4):449–461.
37.Rosenbaum, JF, Fava, M, Hoog, SL, Ascroft, RC, Krebs, WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77–87.
38.Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55.
39.Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389.
40.Khan, A, Khan, SR, Walens, G, Kolts, R, Giller, EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology. 2003;28(3):552–557.
41.Koblan, KS, Hopkins, SC, Sarma, K, et al.Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. Drug Alcohol Depend. 2016;159(2):26–34.
42.National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults–the evidence report. Obes Res. 1998;6(suppl 2):51s–209s.
43.McElroy, SL, Hudson, JI, Capece, JA, et al.Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039–1034.